Noncanonical roles of the immune system in eliciting oncogene addiction

Current Opinion in Immunology

Volumn 25, Issue 2, 2013, Pages 246-258

  Casey, Stephanie C ^a   Bellovin, David I ^a   Felsher, Dean W ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE;

ARTICLE; CANCER GROWTH; CANCER REGRESSION; CARCINOGENESIS; EFFECTOR CELL; GENE ACTIVATION; GENE INACTIVATION; GENE REPRESSION; GENE TARGETING; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOMODULATION; MOLECULARLY TARGETED THERAPY; NONHUMAN; ONCOGENE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

ANIMALS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; ONCOGENES;

EID: 84877084487     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2013.02.003     Document Type: Article

References (171)

1. Jain M., Arvanitis C., Chu K., Dewey W., Leonhardt E., Trinh M., Sundberg C.D., Bishop J.M., Felsher D.W. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 2002, 297:102-104.
2. Shachaf C.M., Kopelman A.M., Arvanitis C., Karlsson A., Beer S., Mandl S., Bachmann M.H., Borowsky A.D., Ruebner B., Cardiff R.D., et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 2004, 431:1112-1117.
3. Hennighausen L., Wall R.J., Tillmann U., Li M., Furth P.A. Conditional gene expression in secretory tissues and skin of transgenic mice using the MMTV-LTR and the tetracycline responsive system. J Cell Biochem 1995, 59:463-472.
4. Felsher D.W., Bishop J.M. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 1999, 4:199-207.
5. Chin L., Tam A., Pomerantz J., Wong M., Holash J., Bardeesy N., Shen Q., O'Hagan R., Pantginis J., Zhou H., et al. Essential role for oncogenic Ras in tumour maintenance. Nature 1999, 400:468-472.
6. D'Cruz C.M., Gunther E.J., Boxer R.B., Hartman J.L., Sintasath L., Moody S.E., Cox J.D., Ha S.I., Belka G.K., Golant A., et al. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med 2001, 7:235-239.
7. Fisher G.H., Wellen S.L., Klimstra D., Lenczowski J.M., Tichelaar J.W., Lizak M.J., Whitsett J.A., Koretsky A., Varmus H.E. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev 2001, 15:3249-3262.
8. Huettner C.S., Zhang P., Van Etten R.A., Tenen D.G. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet 2000, 24:57-60.
9. Marinkovic D., Marinkovic T., Mahr B., Hess J., Wirth T. Reversible lymphomagenesis in conditionally c-MYC expressing mice. Int J Cancer 2004, 110:336-342.
10. Karlsson A., Giuriato S., Tang F., Fung-Weier J., Levan G., Felsher D.W. Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations. Blood 2003, 101:2797-2803.
11. Shachaf C.M., Felsher D.W. Tumor dormancy and MYC inactivation: pushing cancer to the brink of normalcy. Cancer Res 2005, 65:4471-4474.
12. Wu C.H., van Riggelen J., Yetil A., Fan A.C., Bachireddy P., Felsher D.W. Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc Natl Acad Sci U S A 2007, 104:13028-13033.
13. Weinstein I.B., Joe A. Oncogene addiction. Cancer Res 2008, 68:3077-3080. (discussion 3080).
14. Restifo N.P. Can antitumor immunity help to explain 'oncogene addiction'?. Cancer Cell 2010, 18:403-405.
15. Felsher D.W. MYC inactivation elicits oncogene addiction through both tumor cell-intrinsic and host-dependent mechanisms. Genes Cancer 2010, 1:597-604.
16. Rakhra K., Bachireddy P., Zabuawala T., Zeiser R., Xu L., Kopelman A., Fan A.C., Yang Q., Braunstein L., Crosby E., et al. CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell 2010, 18:485-498.
17. Shankaran V., Ikeda H., Bruce A.T., White J.M., Swanson P.E., Old L.J., Schreiber R.D. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001, 410:1107-1111.
18. de Visser K.E., Korets L.V., Coussens L.M. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 2005, 7:411-423.
19. Dougan M., Li D., Neuberg D., Mihm M., Googe P., Wong K.K., Dranoff G. A dual role for the immune response in a mouse model of inflammation-associated lung cancer. J Clin Invest 2011, 121:2436-2446.
20. Ruffell B., DeNardo D.G., Affara N.I., Coussens L.M. Lymphocytes in cancer development: polarization towards pro-tumor immunity. Cytokine Growth Factor Rev 2010, 21:3-10.
21. Zitvogel L., Kepp O., Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 2011, 8:151-160.
22. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pages C., Tosolini M., Camus M., Berger A., Wind P., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964.
23. Dave S.S., Wright G., Tan B., Rosenwald A., Gascoyne R.D., Chan W.C., Fisher R.I., Braziel R.M., Rimsza L.M., Grogan T.M., et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004, 351:2159-2169.
24. Bellovin D.I., Das B., Felsher D.W. Tumor dormancy, oncogene addiction, cellular senescence, and self-renewal programs. Adv Exp Med Biol 2013, 734:91-107.
25. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
26. Weinstein I.B. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 2002, 297:63-64.
27. Felsher D.W. Reversing cancer from inside and out: oncogene addiction, cellular senescence, and the angiogenic switch. Lymphat Res Biol 2008, 6:149-154.
28. Choi P.S., van Riggelen J., Gentles A.J., Bachireddy P., Rakhra K., Adam S.J., Plevritis S.K., Felsher D.W. Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction. Proc Natl Acad Sci U S A 2011, 108:17432-17437.
29. Shortt J., Johnstone R.W. Oncogenes in cell survival and cell death. Cold Spring Harb Perspect Biol 2012, 4:a009829.
30. Baker S.J., Reddy E.P. Targeted inhibition of kinases in cancer therapy. Mt Sinai J Med 2010, 77:573-586.
31. Houshmand P., Zlotnik A. Targeting tumor cells. Curr Opin Cell Biol 2003, 15:640-644.
32. Tran P.T., Bendapudi P.K., Lin H.J., Choi P., Koh S., Chen J., Horng G., Hughes N.P., Schwartz L.H., Miller V.A., et al. Survival and death signals can predict tumor response to therapy after oncogene inactivation. Sci Transl Med 2011, 3:ra199.
33. Bozic I., Antal T., Ohtsuki H., Carter H., Kim D., Chen S., Karchin R., Kinzler K.W., Vogelstein B., Nowak M.A. Accumulation of driver and passenger mutations during tumor progression. Proc Natl Acad Sci U S A 2010, 107:18545-18550.
34. Wood L.D., Parsons D.W., Jones S., Lin J., Sjoblom T., Leary R.J., Shen D., Boca S.M., Barber T., Ptak J., et al. The genomic landscapes of human breast and colorectal cancers. Science 2007, 318:1108-1113.
35. Foltz G., Ryu G.Y., Yoon J.G., Nelson T., Fahey J., Frakes A., Lee H., Field L., Zander K., Sibenaller Z., et al. Genome-wide analysis of epigenetic silencing identifies BEX1 and BEX2 as candidate tumor suppressor genes in malignant glioma. Cancer Res 2006, 66:6665-6674.
36. Felsher D.W. Cancer revoked: oncogenes as therapeutic targets. Nat Rev Cancer 2003, 3:375-380.
37. Sharma S.V., Settleman J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev 2007, 21:3214-3231.
38. Blay J.Y., Le Cesne A., Alberti L., Ray-Coquart I. Targeted cancer therapies. Bull Cancer 2005, 92:E13-E18.
39. Soria J.C., Blay J.Y., Spano J.P., Pivot X., Coscas Y., Khayat D. Added value of molecular targeted agents in oncology. Ann Oncol 2011, 22:1703-1716.
40. Nagai S., Takahashi T., Kurokawa M. The impact of molecularly targeted therapies upon the understanding of leukemogenesis and the role of hematopoietic stem cell transplantation in acute promyelocytic leukemia. Curr Stem Cell Res Ther 2010, 5:372-378.
41. Bollag G., Tsai J., Zhang J., Zhang C., Ibrahim P., Nolop K., Hirth P. Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov 2012, 11:873-886.
42. McCormick F. Cancer therapy based on oncogene addiction. J Surg Oncol 2011, 103:464-467.
43. Hoeflich K.P., Gray D.C., Eby M.T., Tien J.Y., Wong L., Bower J., Gogineni A., Zha J., Cole M.J., Stern H.M., et al. Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res 2006, 66:999-1006.
44. Boxer R.B., Jang J.W., Sintasath L., Chodosh L.A. Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. Cancer Cell 2004, 6:577-586.
45. Giuriato S., Ryeom S., Fan A.C., Bachireddy P., Lynch R.C., Rioth M.J., van Riggelen J., Kopelman A.M., Passegue E., Tang F., et al. Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. Proc Natl Acad Sci U S A 2006, 103:16266-16271.
46. Shchors K., Shchors E., Rostker F., Lawlor E.R., Brown-Swigart L., Evan G.I. The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1beta. Genes Dev 2006, 20:2527-2538.
47. Tran P.T., Fan A.C., Bendapudi P.K., Koh S., Komatsubara K., Chen J., Horng G., Bellovin D.I., Giuriato S., Wang C.S., et al. Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas. PLoS ONE 2008, 3:e2125.
48. Hait W.N., Hambley T.W. Targeted cancer therapeutics. Cancer Res 2009, 69:1263-1267. (discussion 1267).
49. Sawyers C. Targeted cancer therapy. Nature 2004, 432:294-297.
50. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., Lydon N.B., Kantarjian H., Capdeville R., Ohno-Jones S., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344:1031-1037.
51. Hudis C.A. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007, 357:39-51.
52. Chapman P.B., Hauschild A., Robert C., Haanen J.B., Ascierto P., Larkin J., Dummer R., Garbe C., Testori A., Maio M., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2516.
53. Felsher D.W. Reversibility of oncogene-induced cancer. Curr Opin Genet Dev 2004, 14:37-42.
54. Sharma S.V., Settleman J. Oncogenic shock: turning an activated kinase against the tumor cell. Cell Cycle 2006, 5:2878-2880.
55. Kaelin W.G. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005, 5:689-698.
56. Albini A., Sporn M.B. The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer 2007, 7:139-147.
57. Coussens L.M., Tinkle C.L., Hanahan D., Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000, 103:481-490.
58. Bissell M.J., Radisky D. Putting tumours in context. Nat Rev Cancer 2001, 1:46-54.
59. Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001, 357:539-545.
60. Khatami M. 'Yin and Yang' in inflammation: duality in innate immune cell function and tumorigenesis. Expert Opin Biol Ther 2008, 8:1461-1472.
61. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002, 3:991-998.
62. Schreiber R.D., Old L.J., Smyth M.J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011, 331:1565-1570.
63. Llera A.S., Girotti M.R., Benedetti L.G., Podhajcer O.L. Matricellular proteins and inflammatory cells: a task force to promote or defeat cancer?. Cytokine Growth Factor Rev 2010, 21:67-76.
64. Liao Y.P., Schaue D., McBride W.H. Modification of the tumor microenvironment to enhance immunity. Front Biosci 2007, 12:3576-3600.
65. de Visser K.E., Eichten A., Coussens L.M. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006, 6:24-37.
66. Andreu P., Johansson M., Affara N.I., Pucci F., Tan T., Junankar S., Korets L., Lam J., Tawfik D., DeNardo D.G., et al. FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell 2010, 17:121-134.
67. Girardi M., Oppenheim D., Glusac E.J., Filler R., Balmain A., Tigelaar R.E., Hayday A.C. Characterizing the protective component of the alphabeta T cell response to transplantable squamous cell carcinoma. J Invest Dermatol 2004, 122:699-706.
68. Lin E.Y., Nguyen A.V., Russell R.G., Pollard J.W. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 2001, 193:727-740.
69. Hung K., Hayashi R., Lafond-Walker A., Lowenstein C., Pardoll D., Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998, 188:2357-2368.
70. Martin-Manso G., Galli S., Ridnour L.A., Tsokos M., Wink D.A., Roberts D.D. Thrombospondin 1 promotes tumor macrophage recruitment and enhances tumor cell cytotoxicity of differentiated U937 cells. Cancer Res 2008, 68:7090-7099.
71. Reimann M., Lee S., Loddenkemper C., Dorr J.R., Tabor V., Aichele P., Stein H., Dorken B., Jenuweins T., Schmitt C.A. Tumor stroma-derived TGF-beta limits Myc-driven lymphomagenesis via Suv39h1-dependent senescence. Cancer Cell 2010, 17:262-272.
72. Zhou P., Qiu J., L'Italien L., Gu D., Hodges D., Chao C.C., Schebye X.M. Mature B cells are critical to T-cell-mediated tumor immunity induced by an agonist anti-GITR monoclonal antibody. J Immunother 2010, 33:789-797.
73. Wu J., Lanier L.L. Natural killer cells and cancer. Adv Cancer Res 2003, 90:127-156.
74. DeNardo D.G., Barreto J.B., Andreu P., Vasquez L., Tawfik D., Kolhatkar N., Coussens L.M. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009, 16:91-102.
75. Condeelis J., Pollard J.W. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006, 124:263-266.
76. Wakabayashi O., Yamazaki K., Oizumi S., Hommura F., Kinoshita I., Ogura S., Dosaka-Akita H., Nishimura M. CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Sci 2003, 94:1003-1009.
77. Zhang J.P., Yan J., Xu J., Pang X.H., Chen M.S., Li L., Wu C., Li S.P., Zheng L. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol 2009, 50:980-989.
78. Monteleone G., Pallone F., Stolfi C. The dual role of inflammation in colon carcinogenesis. Int J Mol Sci 2012, 13:11071-11084.
79. Mantovani A., Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010, 22:231-237.
80. Denkert C., Darb-Esfahani S., Loibl S., Anagnostopoulos I., Johrens K. Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy. Semin Immunopathol 2011, 33:341-351.
81. Betts G., Jones E., Junaid S., El-Shanawany T., Scurr M., Mizen P., Kumar M., Jones S., Rees B., Williams G., et al. Suppression of tumour-specific CD4(+) T cells by regulatory T cells is associated with progression of human colorectal cancer. Gut 2012, 61:1163-1171.
82. Hao N.B., Lu M.H., Fan Y.H., Cao Y.L., Zhang Z.R., Yang S.M. Macrophages in tumor microenvironments and the progression of tumors. Clin Dev Immunol 2012, 2012:948098.
83. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
84. Zhang H., Melamed J., Wei P., Cox K., Frankel W., Bahnson R.R., Robinson N., Pyka R., Liu Y., Zheng P. Concordant down-regulation of proto-oncogene PML and major histocompatibility antigen HLA class I expression in high-grade prostate cancer. Cancer Immun 2003, 3:2.
85. Zheng P., Guo Y., Niu Q., Levy D.E., Dyck J.A., Lu S., Sheiman L.A., Liu Y. Proto-oncogene PML controls genes devoted to MHC class I antigen presentation. Nature 1998, 396:373-376.
86. Sumimoto H., Imabayashi F., Iwata T., Kawakami Y. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med 2006, 203:1651-1656.
87. Boni A., Cogdill A.P., Dang P., Udayakumar D., Njauw C.N., Sloss C.M., Ferrone C.R., Flaherty K.T., Lawrence D.P., Fisher D.E., et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010, 70:5213-5219.
88. Borrello M.G., Alberti L., Fischer A., Degl'innocenti D., Ferrario C., Gariboldi M., Marchesi F., Allavena P., Greco A., Collini P., et al. Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc Natl Acad Sci U S A 2005, 102:14825-14830.
89. Ancrile B., Lim K.H., Counter C.M. Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev 2007, 21:1714-1719.
90. Sparmann A., Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 2004, 6:447-458.
91. Sodir N.M., Swigart L.B., Karnezis A.N., Hanahan D., Evan G.I., Soucek L. Endogenous Myc maintains the tumor microenvironment. Genes Dev 2011, 25:907-916.
92. Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Regnani G., Makrigiannakis A., Gray H., Schlienger K., Liebman M.N., et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003, 348:203-213.
93. Naito Y., Saito K., Shiiba K., Ohuchi A., Saigenji K., Nagura H., Ohtani H. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998, 58:3491-3494.
94. Pages F., Berger A., Camus M., Sanchez-Cabo F., Costes A., Molidor R., Mlecnik B., Kirilovsky A., Nilsson M., Damotte D., et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005, 353:2654-2666.
95. Nakano O., Sato M., Naito Y., Suzuki K., Orikasa S., Aizawa M., Suzuki Y., Shintaku I., Nagura H., Ohtani H. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res 2001, 61:5132-5136.
96. Dieu-Nosjean M.C., Antoine M., Danel C., Heudes D., Wislez M., Poulot V., Rabbe N., Laurans L., Tartour E., de Chaisemartin L., et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008, 26:4410-4417.
97. Obeid M., Tesniere A., Ghiringhelli F., Fimia G.M., Apetoh L., Perfettini J.L., Castedo M., Mignot G., Panaretakis T., Casares N., et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007, 13:54-61.
98. Shiao S.L., Coussens L.M. The tumor-immune microenvironment and response to radiation therapy. J Mammary Gland Biol Neoplasia 2010, 15:411-421.
99. Fridman W.H., Galon J., Pages F., Tartour E., Sautes-Fridman C., Kroemer G. Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res 2011, 71:5601-5605.
100. Boshoff C., Weiss R. AIDS-related malignancies. Nat Rev Cancer 2002, 2:373-382.
101. Ray-Coquard I., Cropet C., Van Glabbeke M., Sebban C., Le Cesne A., Judson I., Tredan O., Verweij J., Biron P., Labidi I., et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res 2009, 69:5383-5391.
102. Soucek L., Lawlor E.R., Soto D., Shchors K., Swigart L.B., Evan G.I. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med 2007, 13:1211-1218.
103. Charo J., Blankenstein T. Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer. Cancer Cell 2011, 20:755-767.
104. Blankenstein T., Anders K. Molecular pathways: comparing the effects of drugs and T cells to effectively target oncogenes. Clin Cancer Res 2013, 19:320-326.
105. Gerbitz A., Sukumar M., Helm F., Wilke A., Friese C., Fahrenwaldt C., Lehmann F.M., Loddenkemper C., Kammertoens T., Mautner J., et al. Stromal interferon-gamma signaling and cross-presentation are required to eliminate antigen-loss variants of B cell lymphomas in mice. PLoS ONE 2012, 7:e34552.
106. Jaime-Ramirez A.C., Mundy-Bosse B.L., Kondadasula S., Jones N.B., Roda J.M., Mani A., Parihar R., Karpa V., Papenfuss T.L., LaPerle K.M., et al. IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-gamma production. J Immunol 2011, 186:3401-3409.
107. Tamada K., Chen L. Renewed interest in cancer immunotherapy with the tumor necrosis factor superfamily molecules. Cancer Immunol Immunother 2006, 55:355-362.
108. Vinay D.S., Kwon B.S. Immunotherapy of cancer with 4-1BB. Mol Cancer Ther 2012, 11:1062-1070.
109. Takeda K., Okumura K., Smyth M.J. Combination antibody-based cancer immunotherapy. Cancer Sci 2007, 98:1297-1302.
110. Kohrt H.E., Houot R., Weiskopf K., Goldstein M.J., Scheeren F., Czerwinski D., Colevas A.D., Weng W.K., Clarke M.F., Carlson R.W., et al. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest 2012, 122:1066-1075.
111. Taylor C., Hershman D., Shah N., Suciu-Foca N., Petrylak D.P., Taub R., Vahdat L., Cheng B., Pegram M., Knutson K.L., et al. Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin Cancer Res 2007, 13:5133-5143.
112. Park S., Jiang Z., Mortenson E.D., Deng L., Radkevich-Brown O., Yang X., Sattar H., Wang Y., Brown N.K., Greene M., et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010, 18:160-170.
113. Ladoire S., Arnould L., Mignot G., Apetoh L., Rebe C., Martin F., Fumoleau P., Coudert B., Ghiringhelli F. T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival. Br J Cancer 2011, 105:366-371.
114. Ullrich E., Bonmort M., Mignot G., Chaput N., Taieb J., Menard C., Viaud S., Tursz T., Kroemer G., Zitvogel L. Therapy-induced tumor immunosurveillance involves IFN-producing killer dendritic cells. Cancer Res 2007, 67:851-853.
115. Catellani S., Pierri I., Gobbi M., Poggi A., Zocchi M.R. Imatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia. PLoS ONE 2011, 6:e18925.
116. Maggio R., Peragine N., De Propris M.S., Vitale A., Elia L., Calabrese E., Della Starza I., Intoppa S., Milani M.L., Guarini A., et al. Immunocompetent cell functions in Ph+ acute lymphoblastic leukemia patients on prolonged Imatinib maintenance treatment. Cancer Immunol Immunother 2011, 60:599-607.
117. Muranski P., Restifo N.P. Adoptive immunotherapy of cancer using CD4(+) T cells. Curr Opin Immunol 2009, 21:200-208.
118. Bachireddy P., Rakhra K., Felsher D.W. Immunology in the clinic review series; focus on cancer: multiple roles for the immune system in oncogene addiction. Clin Exp Immunol 2012, 167:188-194.
119. Acosta J.C., O'Loghlen A., Banito A., Guijarro M.V., Augert A., Raguz S., Fumagalli M., Da Costa M., Brown C., Popov N., et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 2008, 133:1006-1018.
120. Beatty G., Paterson Y. IFN-gamma-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-gamma. J Immunol 2001, 166:2276-2282.
121. Kuilman T., Michaloglou C., Vredeveld L.C., Douma S., van Doorn R., Desmet C.J., Aarden L.A., Mooi W.J., Peeper D.S. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 2008, 133:1019-1031.
122. Muller-Hermelink N., Braumuller H., Pichler B., Wieder T., Mailhammer R., Schaak K., Ghoreschi K., Yazdi A., Haubner R., Sander C.A., et al. TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell 2008, 13:507-518.
123. Li S.S., Ivanoff A., Bergstrom S.E., Sandstrom A., Christensson B., van Nerven J., Holgersson J., Hauzenberger D., Arencibia I., Sundqvist K.G. T lymphocyte expression of thrombospondin-1 and adhesion to extracellular matrix components. Eur J Immunol 2002, 32:1069-1079.
124. Li S.S., Liu Z., Uzunel M., Sundqvist K.G. Endogenous thrombospondin-1 is a cell-surface ligand for regulation of integrin-dependent T-lymphocyte adhesion. Blood 2006, 108:3112-3120.
125. Young G.D., Murphy-Ullrich J.E. The tryptophan-rich motifs of the thrombospondin type 1 repeats bind VLAL motifs in the latent transforming growth factor-beta complex. J Biol Chem 2004, 279:47633-47642.
126. Becker C., Fantini M.C., Schramm C., Lehr H.A., Wirtz S., Nikolaev A., Burg J., Strand S., Kiesslich R., Huber S., et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 2004, 21:491-501.
127. Tang B., Yoo N., Vu M., Mamura M., Nam J.S., Ooshima A., Du Z., Desprez P.Y., Anver M.R., Michalowska A.M., et al. Transforming growth factor-beta can suppress tumorigenesis through effects on the putative cancer stem or early progenitor cell and committed progeny in a breast cancer xenograft model. Cancer Res 2007, 67:8643-8652.
128. van Riggelen J., Muller J., Otto T., Beuger V., Yetil A., Choi P.S., Kosan C., Moroy T., Felsher D.W., Eilers M. The interaction between Myc and Miz1 is required to antagonize TGFbeta-dependent autocrine signaling during lymphoma formation and maintenance. Genes Dev 2010, 24:1281-1294.
129. Markovic S.N., Suman V.J., Rao R.A., Ingle J.N., Kaur J.S., Erickson L.A., Pitot H.C., Croghan G.A., McWilliams R.R., Merchan J., et al. A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma. Am J Clin Oncol 2007, 30:303-309.
130. Xue W., Zender L., Miething C., Dickins R.A., Hernando E., Krizhanovsky V., Cordon-Cardo C., Lowe S.W. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007, 445:656-660.
131. Kerkar S.P., Muranski P., Kaiser A., Boni A., Sanchez-Perez L., Yu Z., Palmer D.C., Reger R.N., Borman Z.A., Zhang L., et al. Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res 2010, 70:6725-6734.
132. Zhang L., Yu Z., Muranski P., Palmer D.C., Restifo N.P., Rosenberg S.A., Morgan R.A. Inhibition of TGF-beta signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy. Gene Ther 2012, [Epub ahead of print]. 10.1038/gt.2012.75.
133. Gattinoni L., Klebanoff C.A., Restifo N.P. Paths to stemness: building the ultimate antitumour T cell. Nat Rev Cancer 2012, 12:671-684.
134. Klebanoff C.A., Gattinoni L., Restifo N.P. Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?. J Immunother 2012, 35:651-660.
135. Emens L.A., Silverstein S.C., Khleif S., Marincola F.M., Galon J. Toward integrative cancer immunotherapy: targeting the tumor microenvironment. J Transl Med 2012, 10:70.
136. Mlecnik B., Tosolini M., Kirilovsky A., Berger A., Bindea G., Meatchi T., Bruneval P., Trajanoski Z., Fridman W.H., Pages F., et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 2011, 29:610-618.
137. Kerkar S.P., Goldszmid R.S., Muranski P., Chinnasamy D., Yu Z., Reger R.N., Leonardi A.J., Morgan R.A., Wang E., Marincola F.M., et al. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest 2011, 121:4746-4757.
138. Klebanoff C.A., Gattinoni L., Palmer D.C., Muranski P., Ji Y., Hinrichs C.S., Borman Z.A., Kerkar S.P., Scott C.D., Finkelstein S.E., et al. Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. Clin Cancer Res 2011, 17:5343-5352.
139. Beano A., Signorino E., Evangelista A., Brusa D., Mistrangelo M., Polimeni M.A., Spadi R., Donadio M., Ciuffreda L., Matera L. Correlation between NK function and response to trastuzumab in metastatic breast cancer patients. J Transl Med 2008, 6:25.
140. Kajitani K., Tanaka Y., Arihiro K., Kataoka T., Ohdan H. Mechanistic analysis of the antitumor efficacy of human natural killer cells against breast cancer cells. Breast Cancer Res Treat 2012, 134:139-155.
141. Hayashi Y., Nakamae H., Katayama T., Nakane T., Koh H., Nakamae M., Hirose A., Hagihara K., Terada Y., Nakao Y., et al. Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib. Leuk Lymphoma 2012, 53:1084-1089.
142. Ohyashiki K., Katagiri S., Tauchi T., Ohyashiki J.H., Maeda Y., Matsumura I., Kyo T. Increased natural killer cells and decreased CD3(+)CD8(+)CD62L(+) T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib. Br J Haematol 2012, 157:254-256.
143. Hannani D., Ma Y., Yamazaki T., Dechanet-Merville J., Kroemer G., Zitvogel L. Harnessing gammadelta T cells in anticancer immunotherapy. Trends Immunol 2012, 33:199-206.
144. Mellman I., Coukos G., Dranoff G. Cancer immunotherapy comes of age. Nature 2011, 480:480-489.
145. Topp M.S., Kufer P., Gokbuget N., Goebeler M., Klinger M., Neumann S., Horst H.A., Raff T., Viardot A., Schmid M., et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011, 29:2493-2498.
146. Franz B., May K.F., Dranoff G., Wucherpfennig K. Ex vivo characterization and isolation of rare memory B cells with antigen tetramers. Blood 2011, 118:348-357.
147. Schoenfeld J., Jinushi M., Nakazaki Y., Wiener D., Park J., Soiffer R., Neuberg D., Mihm M., Hodi F.S., Dranoff G. Active immunotherapy induces antibody responses that target tumor angiogenesis. Cancer Res 2010, 70:10150-10160.
148. Menard C., Blay J.Y., Borg C., Michiels S., Ghiringhelli F., Robert C., Nonn C., Chaput N., Taieb J., Delahaye N.F., et al. Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. Cancer Res 2009, 69:3563-3569.
149. Balachandran V.P., Cavnar M.J., Zeng S., Bamboat Z.M., Ocuin L.M., Obaid H., Sorenson E.C., Popow R., Ariyan C., Rossi F., et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med 2011, 17:1094-1100.
150. Wilmott J.S., Long G.V., Howle J.R., Haydu L.E., Sharma R.N., Thompson J.F., Kefford R.F., Hersey P., Scolyer R.A. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 2012, 18:1386-1394.
151. Wilmott J.S., Scolyer R.A., Long G.V., Hersey P. Combined targeted therapy and immunotherapy in the treatment of advanced melanoma. Oncoimmunology 2012, 1:997-999.
152. Liu C., Peng W., Xu C., Lou Y., Zhang M., Wargo J.A., Chen J., Li H.S., Watowich S., Yang Y., et al. BRAF inhibition increases tumor infiltration by T cells and enhances the anti-tumor activity of adoptive immunotherapy in mice. Clin Cancer Res 2013, 19:393-403.
153. Comin-Anduix B., Chodon T., Sazegar H., Matsunaga D., Mock S., Jalil J., Escuin-Ordinas H., Chmielowski B., Koya R.C., Ribas A. The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. Clin Cancer Res 2010, 16:6040-6048.
154. Bajor D.L., Vonderheide R.H. Rehabilitation for oncogene addiction: role of immunity in cellular sobriety. Clin Cancer Res 2012, 18:1192-1194.
155. Kaufmann T., Strasser A., Jost P.J. Fas death receptor signalling: roles of Bid and XIAP. Cell Death Differ 2012, 19:42-50.
156. Gregory C.D., Pound J.D. Microenvironmental influences of apoptosis in vivo and in vitro. Apoptosis 2010, 15:1029-1049.
157. Spisek R., Dhodapkar M.V. Towards a better way to die with chemotherapy: role of heat shock protein exposure on dying tumor cells. Cell Cycle 2007, 6:1962-1965.
158. Michaud M., Martins I., Sukkurwala A.Q., Adjemian S., Ma Y., Pellegatti P., Shen S., Kepp O., Scoazec M., Mignot G., et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011, 334:1573-1577.
159. Menger L., Vacchelli E., Adjemian S., Martins I., Ma Y., Shen S., Yamazaki T., Sukkurwala A.Q., Michaud M., Mignot G., et al. Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. Sci Transl Med 2012, 4:143ra199.
160. Apetoh L., Ghiringhelli F., Tesniere A., Criollo A., Ortiz C., Lidereau R., Mariette C., Chaput N., Mira J.P., Delaloge S., et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev 2007, 220:47-59.
161. Ghiringhelli F., Apetoh L., Tesniere A., Aymeric L., Ma Y., Ortiz C., Vermaelen K., Panaretakis T., Mignot G., Ullrich E., et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009, 15:1170-1178.
162. Gardai S.J., McPhillips K.A., Frasch S.C., Janssen W.J., Starefeldt A., Murphy-Ullrich J.E., Bratton D.L., Oldenborg P.A., Michalak M., Henson P.M. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 2005, 123:321-334.
163. Chao M.P., Jaiswal S., Weissman-Tsukamoto R., Alizadeh A.A., Gentles A.J., Volkmer J., Weiskopf K., Willingham S.B., Raveh T., Park C.Y., et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med 2010, 2:ra94.
164. Bianchi M.E. HMGB1 loves company. J Leukoc Biol 2009, 86:573-576.
165. Mutini C., Falzoni S., Ferrari D., Chiozzi P., Morelli A., Baricordi O.R., Collo G., Ricciardi-Castagnoli P., Di Virgilio F. Mouse dendritic cells express the P2X7 purinergic receptor: characterization and possible participation in antigen presentation. J Immunol 1999, 163:1958-1965.
166. Chien Y., Scuoppo C., Wang X., Fang X., Balgley B., Bolden J.E., Premsrirut P., Luo W., Chicas A., Lee C.S., et al. Control of the senescence-associated secretory phenotype by NF-kappaB promotes senescence and enhances chemosensitivity. Genes Dev 2011, 25:2125-2136.
167. Mooi W.J., Peeper D.S. Oncogene-induced cell senescence-halting on the road to cancer. N Engl J Med 2006, 355:1037-1046.
168. Tiwari N., Gheldof A., Tatari M., Christofori G. EMT as the ultimate survival mechanism of cancer cells. Semin Cancer Biol 2012, 22:194-207.
169. Wrzesinski C., Paulos C.M., Kaiser A., Muranski P., Palmer D.C., Gattinoni L., Yu Z., Rosenberg S.A., Restifo N.P. Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J Immunother 2010, 33:1-7.
170. Vanneman M., Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012, 12:237-251.
171. Lindencrona J.A., Preiss S., Kammertoens T., Schuler T., Piechocki M., Wei W.Z., Seliger B., Blankenstein T., Kiessling R. CD4+ T cell-mediated HER-2/neu-specific tumor rejection in the absence of B cells. Int J Cancer 2004, 109:259-264.